Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Biotechnology

Healthcare
$42.99 +5.87%

+$4.49 today

Market cap
$6.08B
Beta
1.27
P/E (TTM)
-38.4
EPS (TTM)
-$2.11
52W Low $14.30High $82.48

Volume 3.70M

Average 1.82M

ARWR EBITDA Margin

EBITDA as a percentage of revenue.

Arrowhead Pharmaceuticals, Inc.NASDAQ: ARWR

EBITDA Margin · Q4 FY2026 · quarter ended Sep 2026

EBITDA Margin narrows to -1073.5%

EBITDA Margin was -1073.5% in Q4 FY2026, down 1098.5 pp from a year earlier. On a trailing-twelve-month basis it was -133.9%, down 153.8 pp year over year. Over 3 fiscal years it narrowed by 60.9 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 9 analysts of -216.5% for the fiscal year ending Sep 2027, down from -133.9% in FY2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-1073.5%-877.2 pp QoQ
Last fiscal yearSep 2026
-133.9%-153.8 pp YoY
LTMSep 2026
-133.9%-153.8 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1098.5 pp-84.8 pp+1013.7 pp
1 year-153.8 pp-82.6 pp+71.1 pp
3 years-60.9 pp+129.2 pp+190.2 pp
5 years+201.0 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2026
-133.9%
Year-over-year change
-153.8pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How ARWR compares with its peers on the latest reported figures

  • ARWR's LTM Sep 2026 EBITDA Margin of -133.9% is the 3rd highest of the 7 companies compared; the peer median is -196.0%.
  • Its year-over-year change of -153.8 pp is the 5th highest of 6, against a peer median of -100.7 pp.
  • Over three fiscal years its change of -60.9 pp compares with a peer median of +57.5 pp.
ARWR Competitors Peer median
EBITDA Margin for ARWR and competitors
Company Period LTM level YoY 3-year change
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 202624.0% +30.9 pp+106.3 pp
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-49.3% -33.5 pp+8.7 pp
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026-133.9% -153.8 pp-60.9 pp
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-148.9% -100.7 pp-100.7 pp
WVEWave Life Sciences Ltd.LTM Mar 2026-243.2% -144.4 pp+3681.3 pp
PRQRProQR Therapeutics N.V.LTM Mar 2026-319.0% -184.3 pp+1328.5 pp
SLNSilence Therapeutics plcLTM Mar 2026-8478.5% —-15524.4 pp
Peer median (excluding ARWR) -196.0%-100.7 pp+57.5 pp

Competitors are the stored peer set for ARWR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Revenue243.23M240.74M3.55M829.45M450.82M
Cost of Revenue10.42M12.49M18.6M01.8M
Gross Profit232.81M228.24M(15.04M)829.45M449.02M
Gross Margin95.7%94.8%-423.7%100.0%99.6%
Research & Development288.5M342.31M489.22M607.16M739.14M
Selling, General & Admin124.43M90.93M96.82M121.92M202.05M
Operating Expenses411.32M433.24M586.04M731.1M1.16B
Depreciation & Amortization10.42M12.49M18.6M23.93M26.62M
EBITDA(162.29M)(175.67M)(561.51M)164.82M(603.59M)
EBITDA Margin-66.7%-73.0%-15812.8%19.9%-133.9%
Operating Income(178.51M)(205M)(601.08M)98.35M(707.17M)
Operating Margin-73.4%-85.2%-16927.1%11.9%-156.9%
Interest Income5.03M15.3M22.72M37.29M57.86M
Interest Expense018.33M32.35M89.36M93.71M
Other Income / Expenses5.8M(1.49M)(11.38M)(46.81M)(16.74M)
Income Before Tax(172.71M)(206.49M)(612.46M)51.53M(723.92M)
Pre-Tax Margin-71.0%-85.8%-17247.5%6.2%-160.6%
Income Tax Expense3.79M2.78M(2.77M)21.42M(6.78M)
Net Income(176.06M)(205.28M)(599.49M)(1.63M)(724.21M)
Net Margin-72.4%-85.3%-16882.4%-0.2%-160.6%
EPS (Basic)(1.67)(1.92)(5.00)(0.01)(5.11)
EPS (Diluted)(1.67)(1.92)(5.00)(0.01)(5.11)
Weighted Avg Shares105.43M106.75M119.78M133.76M141.63M
Weighted Avg Shares (Diluted)105.43M106.75M119.78M133.76M141.63M

Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Intrinsic Alpha fair value

Locked

Current Price

$42.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.